Downregulated Stromal Antigen 2 Expression in De Novo Acute Myeloid Leukemia Patients

Experimental and Therapeutic Medicine - Greece
doi 10.3892/etm.2017.4030
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Splicing Factor Mutations Predict Poor Prognosis in Patients With De Novo Acute Myeloid Leukemia

Oncotarget
Oncology
2016English

Anthracycline Versus Non-Anthracycline Induction Regimens in Patients With De Novo Acute Myeloid Leukemia

Middle East Journal of Internal Medicine
2017English

Prognostic Significance of WT1 Gene Expression at Diagnosis in Adult De Novo Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1997English

SALL1 Expression in Acute Myeloid Leukemia

Oncotarget
Oncology
2017English

Evaluation of P21Cip1 and P27Kip1 Expression in De Novo Acute Lymphoblastic Leukemia Patients

Biomedical Research and Therapy
BiochemistryMedicineGeneticsMolecular Biology
2018English

Inferior Outcome of Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in First Complete Remission as Compared to De Novo Acute Myeloid Leukemia

Blood Cancer Journal
OncologyHematology
2020English

Prognostic Impact of MYH9 Expression on Patients With Acute Myeloid Leukemia

Oncotarget
Oncology
2016English

De Novo Philadelphia Positive Acute Myeloid Leukemia With Extensive Basophilia: A Diagnostic Dilemma

Indian Journal of Hematology and Blood Transfusion
Hematology
2016English

Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy